Who was studied?
One patient with oligometastatic platinum-resistant ovarian cancer.
What does the publication report?
A partial response and benefit lasting more than six months were described.
Safety findings
Detailed graded adverse-event information is not supplied in the abstract.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer · DOI: 10.3389/fimmu.2023.1329951 · PMID: 38235148
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.